{"id":"e713e6696b22","type":"article","url":"https://hartvaat.nl/2026/11/07/digitale-aanpak-verhoogt-sglt2i-voorschrijving-bij-hartfalen-email-hf/","title":"Digitale aanpak verhoogt SGLT2i-voorschrijving bij hartfalen — EMAIL-HF","title_en":"EMAIL-HF: Can Digital Strategies Shorten the Path from Scientific Evidence to Clinical Practice in Heart Failure?","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"Heart failure reviews","doi":"10.1007/s10741-026-10691-7","source_url":"https://doi.org/10.1007/s10741-026-10691-7","authors":["Monica T A Albuquerque","Patricia O Guimaraes","Caio A M Tavares","Vagner Madrini","Eduardo B Martins","Kalliopi Keramida","Dike Ojji","Kaveh Hosseini","Luca Monzo","Francesca Musella","Yasuhiko Sakata","Mario Enrico Canonico","Tamas Alexy","Jan Biegus","Savina Nodari","Andrew Ambrosy","Mitja Lainscak"],"significance":6,"published":"2026-11-15","source_date":"2026-11-07","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/hfref-hartfalen-met-verminderde-ejectie/","https://hartvaat.nl/kennis/hartfalen/acuut-hartfalen/"],"congress":"","summary_en":"The EMAIL-HF trial evaluated whether a digital intervention—consisting of an informational e-mail about SGLT2 inhibitors followed by specialist contact—accelerates prescription uptake in patients with heart failure. While the strategy significantly increased SGLT2i initiation within six months, it did not reduce heart failure hospitalizations or all-cause mortality over 24 months. The findings highlight that improving medication adherence through digital tools does not automatically translate into hard clinical outcomes, yet remains a practical approach to closing the evidence-practice gap in heart failure management.","created":"2026-11-09T02:04:05Z","updated":"2026-11-09T02:04:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De EMAIL-HF-studie onderzocht of een digitale interventie (e-mail met informatie over SGLT2-remmers gevolgd door contact met een hartfalen specialist) het voorschrijven van deze medicatie bij patiënten met hartfalen kan versnellen. Hoewel de aanpak het gebruik binnen zes maanden significant verhoogde, leidde dit niet tot minder hartfalen-opnames of sterfte na twee jaar. Dit benadrukt dat verbeterde medicatie-uptake niet automatisch vertaalt naar betere klinische uitkomsten, maar blijft wel een relevant instrument om de implementatie van bewezen therapieën in de dagpraktijk te stimuleren.","abstract_original":"A substantial gap persists between scientific evidence and clinical practice in heart failure (HF). Digital solutions have emerged as promising strategies to accelerate the implementation of evidence-based therapies. This mini-review examines the results of the EMAIL-HF study, a registry-based, randomized, controlled, parallel-group clinical trial conducted in Denmark that included patients aged 20 years or older with a diagnosis of HF irrespective of left ventricular ejection fraction, who were not receiving SGLT2 inhibitors (SGLT2i). Participants were randomized to usual care or a digital strategy consisting of an e-mailed letter with information on SGLT2i, followed by contact with an HF specialist. The primary endpoint was the proportion of patients redeeming a prescription for dapagliflozin or empagliflozin within 6 months of randomization and the secondary endpoint was a composite of time to first HF hospitalization or death from any cause. The digital strategy significantly increased SGLT2i initiation within 6 months, although no difference in HF hospitalization or all-cause mortality was observed during the 24-month follow-up. Whether these strategies can translate modest improvements in treatment uptake into sustained, scalable, and cost-effective gains across diverse healthcare systems remains uncertain."}